Pulmonary Vein Isolation With and Without Posterior Wall Isolation in Paroxysmal Atrial Fibrillation: IMPPROVE-PAF Trial.

catheter ablation cryoballoon paroxysmal atrial fibrillation posterior wall isolation pulmonary vein isolation

Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
05 2023
Historique:
received: 27 06 2022
revised: 13 01 2023
accepted: 18 01 2023
medline: 26 5 2023
pubmed: 25 5 2023
entrez: 24 5 2023
Statut: ppublish

Résumé

Prior studies have demonstrated clinical benefits associated with cryoballoon pulmonary vein isolation (PVI) and concomitant posterior wall isolation (PWI) in patients with persistent atrial fibrillation (AF). However, the role for this approach in patients with paroxysmal atrial fibrillation (PAF) remains unclear. This study investigated the acute and long-term outcomes of PVI vs PVI+PWI using cryoballoon in patients with symptomatic PAF. This retrospective study (NCT05296824) examined the outcomes of cryoballoon PVI (n = 1,342) vs cryoballoon PVI+PWI (n = 442) in patients with symptomatic PAF during long-term follow-up. Using the nearest-neighbor method, a 1:1 matched sample of patients receiving PVI alone and PVI+PWI was created. The matched cohort consisted of 320 patients (PVI: n = 160; PVI+PWI: n = 160). PVI+PWI was associated with longer cryoablation (23 ± 10 minutes vs 42 ± 11 minutes; P < 0.001) and procedure times (103 ± 24 minutes vs 127 ± 14 minutes; P < 0.001). In 39 (24.4%) of 160 patients, adjunct radiofrequency ablation was required for PVI+PWI. Adverse event rates were similar (PVI 3.8% vs PVI+PWI 1.9%; P = 0.31). Though there were no differences at 12 months, freedom from all atrial arrhythmias (67.5% vs 45.0%; P < 0.001) and AF (75.6% vs 55.0%; P < 0.001) were significantly greater with PVI+PWI vs PVI alone at 39 ± 9 months of follow-up. PVI+PWI was also associated with reduced long-term need for cardioversion (16.9% vs 27.5%; P = 0.02) and repeat catheter ablation (11.9% vs 26.3%; P = 0.001), and emerged as the only significant predictor of freedom from recurrent AF (HR: 2.79; 95% CI: 1.64-4.74; P < 0.001). Compared with cryoballoon PVI, cryoballoon PVI+PWI appears to be associated with greater freedom from recurrent atrial arrhythmias and AF in patients with PAF during long-term follow-up >3 years.

Sections du résumé

BACKGROUND
Prior studies have demonstrated clinical benefits associated with cryoballoon pulmonary vein isolation (PVI) and concomitant posterior wall isolation (PWI) in patients with persistent atrial fibrillation (AF). However, the role for this approach in patients with paroxysmal atrial fibrillation (PAF) remains unclear.
OBJECTIVES
This study investigated the acute and long-term outcomes of PVI vs PVI+PWI using cryoballoon in patients with symptomatic PAF.
METHODS
This retrospective study (NCT05296824) examined the outcomes of cryoballoon PVI (n = 1,342) vs cryoballoon PVI+PWI (n = 442) in patients with symptomatic PAF during long-term follow-up. Using the nearest-neighbor method, a 1:1 matched sample of patients receiving PVI alone and PVI+PWI was created.
RESULTS
The matched cohort consisted of 320 patients (PVI: n = 160; PVI+PWI: n = 160). PVI+PWI was associated with longer cryoablation (23 ± 10 minutes vs 42 ± 11 minutes; P < 0.001) and procedure times (103 ± 24 minutes vs 127 ± 14 minutes; P < 0.001). In 39 (24.4%) of 160 patients, adjunct radiofrequency ablation was required for PVI+PWI. Adverse event rates were similar (PVI 3.8% vs PVI+PWI 1.9%; P = 0.31). Though there were no differences at 12 months, freedom from all atrial arrhythmias (67.5% vs 45.0%; P < 0.001) and AF (75.6% vs 55.0%; P < 0.001) were significantly greater with PVI+PWI vs PVI alone at 39 ± 9 months of follow-up. PVI+PWI was also associated with reduced long-term need for cardioversion (16.9% vs 27.5%; P = 0.02) and repeat catheter ablation (11.9% vs 26.3%; P = 0.001), and emerged as the only significant predictor of freedom from recurrent AF (HR: 2.79; 95% CI: 1.64-4.74; P < 0.001).
CONCLUSIONS
Compared with cryoballoon PVI, cryoballoon PVI+PWI appears to be associated with greater freedom from recurrent atrial arrhythmias and AF in patients with PAF during long-term follow-up >3 years.

Identifiants

pubmed: 37225309
pii: S2405-500X(23)00069-5
doi: 10.1016/j.jacep.2023.01.014
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT05296824']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

628-637

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Drs Aryana, O’Neill, Ellis, and d’Avila have received consulting fees from Medtronic. Dr Aryana has received research grant support from Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Arash Aryana (A)

Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA. Electronic address: a_aryana@outlook.com.

Anna M Thiemann (AM)

California Northstate University College of Medicine, Elk Grove, California, USA.

Deep K Pujara (DK)

University of Texas Health Science Center at Houston, Houston, Texas, USA.

Laura L Cossette (LL)

Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA.

Shelley L Allen (SL)

Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA.

Mark R Bowers (MR)

Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA.

Maheer Gandhavadi (M)

Overlake Hospital Medical Center, Bellevue, Washington, USA.

Russell Heath (R)

University of Colorado Health, Fort Collins, Colorado, USA.

Amar D Trivedi (AD)

University of Colorado Health, Fort Collins, Colorado, USA.

Padraig Gearoid O'Neill (PG)

Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California, USA.

Ethan R Ellis (ER)

University of Colorado Health, Fort Collins, Colorado, USA.

André d'Avila (A)

Harvard Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH